Obviousness and Pharmaceutical Method of Treatment Claims
Patently O
APRIL 1, 2024
by Dennis Crouch In April 2024, the Federal Circuit issued a significant decision vacating a district court’s judgment that Janssen Pharmaceuticals’ dosing regimen patent claims were nonobvious. The case involved Janson’s U.S. Overall, this is a bad case for pharmaceutical formulary patents. Teva Pharms.
Let's personalize your content